Safety and clinical activity of atezolizumab in head and neck cancer: Results from a phase I trial

Annals of Oncology

Volumn 29, Issue 11, 2018, Pages 2247-2253

  Colevas, A D ^a   Bahleda, R ^b   Braiteh, F ^c   Balmanoukian, A ^d   Brana, I ^e   Chau, N G ^f   Sarkar, I ^g   Molinero, L ^g   Grossman, W ^g,i   Kabbinavar, F ^g   Fasso M ^g   O'Hear C ^g   Powderly, J ^h  

^a STANFORD CANCER INSTITUTE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d Los Angeles Clinical Trials   (United States)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f HARVARD MEDICAL SCHOOL   (United States)

^g GENENTECH INC   (United States)

^h Carolina BioOncology Institute   (United States)

ⁱ With Bellicum Pharmaceuticals Inc   (United States)

Author keywords

Atezolizumab; Head and neck cancer; Human papillomavirus; Programmed death ligand 1; SCCHN; Squamous cell carcinoma

Indexed keywords

ATEZOLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CANCER PAIN; CHILL; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; DIARRHEA; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEAD AND NECK CANCER; HEART TAMPONADE; HUMAN; HYPONATREMIA; HYPOPHARYNX CANCER; LARYNX CANCER; MALE; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NASOPHARYNX CANCER; NAUSEA; OROPHARYNX CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION LEVEL; PRURITUS; RASH; TUMOR LYSIS SYNDROME; VOMITING; WART VIRUS; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; HEAD AND NECK TUMOR; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PAPILLOMAVIRIDAE; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TUMOR MICROENVIRONMENT; VIROLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PROGRESSION-FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TUMOR MICROENVIRONMENT;

EID: 85058596892     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy411     Document Type: Article

References (30)

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3: 524–548.
2. Wollenberg B. Cancer immunology and HPV. Recent Results Cancer Res 2017; 206: 243–248.
3. Tsao SW, Tsang CM, Lo KW. Epstein–Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci 2017; 372: pii: 20160270.
4. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359(11): 1116–1127.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Head and Neck Cancers; version 2.2017; https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (21 November 2017, date last accessed).
6. Opdivo (nivolumab). [Package Insert]. New York, NY: Bristol-Myers Squibb 2017.
7. Cohen EE, Harrington KJ, Le Tourneau C et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial. Ann Oncol 2017; 28(Suppl 5): v605–v649.
8. Keytruda (pembrolizumab). [Package Insert]. Whitehouse Station, NJ: Merck & Co, Inc 2017.
9. Ferris RL, Blumenschein G Jr, Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375(19): 1856–1867.
10. Elicin O, Ozsahin M. The latest prospects of investigational drugs for head and neck cancer. Expert Opin Investig Drugs 2017; 26(3): 265–268.
11. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012; 18(24): 6580–6587.
12. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515(7528): 563–567.
13. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515(7528): 558–562.
14. TECENTRIQ (atezolizumab). [Summary of Product Characteristics]. Welwyn Garden City, UK: Roche Registration Limited 2017.
15. TECENTRIQ (atezolizumab). [Product Insert]. South San Francisco, CA: Genentech, Inc 2017.
16. National Cancer Institute. Common Terminology Criteria for Adverse Events. Version 4.0; https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (31 December 2016, date last accessed).
17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247.
18. Wang-Johanning F, Lu DW, Wang Y et al. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002; 94(8): 2199–2210.
19. Seaman WT, Andrews E, Couch M et al. Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. Virol J 2010; 7: 194.
20. Gravitt PE, Peyton C, Wheeler C et al. Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays. J Virol Methods 2003; 112(1-2): 23–33.
21. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350(24): 2461–2470.
22. Seiwert TY, Burtness B, Mehra R et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17(7): 956–965.
23. Zandberg D, Algazi A, Jimeno A et al. 1042O Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. Ann Oncol 2017; 28(Suppl 5): Abstr 1042O.
24. Delord JP, Hollebecque A, De Boer JP et al. An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). J Clin Oncol 2017; 35(Suppl 15): 6025. Abstr.
25. Hsu C, Lee SH, Ejadi S et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol 2017; 35(36): 4050–4056.
26. Chan OS, Kowanetz M, Ng WT et al. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. Oral Oncol 2017; 67: 52–60.
27. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100(4): 261–269.
28. Cmelak AJ. Current issues in combined modality therapy in locally advanced head and neck cancer. Crit Rev Oncol Hematol 2012; 84(2): 261–273.
29. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363(1): 24–35.
30. Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017; 389(10066): 255–265.